<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The risk of <z:hpo ids='HP_0100726'>Kaposi's sarcoma</z:hpo> and non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> is increased in people infected with the human <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> virus-1 (HIV) </plain></SENT>
<SENT sid="1" pm="."><plain>Highly active antiretroviral therapy (HAART) has been widely used by HIV-infected people in North America, Europe, and Australia since about 1997 </plain></SENT>
<SENT sid="2" pm="."><plain>Acquired <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> syndrome (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>) incidence and mortality rates have fallen markedly in association with the use of HAART, but its impact on the incidence of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in HIV-infected people is less clear </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> incidence data from 23 prospective studies that included 47 936 HIV-seropositive individuals from North America, Europe, and Australia were collated, checked, and analyzed centrally </plain></SENT>
<SENT sid="4" pm="."><plain>Adjusted incidence rates (expressed as number of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> per 1000 person-years) for <z:hpo ids='HP_0100726'>Kaposi's sarcoma</z:hpo>, non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e>, <z:e sem="disease" ids="C0302592" disease_type="Neoplastic Process" abbrv="">cervical cancer</z:e>, and 20 other <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> types or sites were calculated </plain></SENT>
<SENT sid="5" pm="."><plain>Rate ratios were estimated, comparing incidence rates from 1997 through 1999 with rates from 1992 through 1996, after adjustment for study, age, sex, and HIV transmission group </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> statistical tests were two-sided </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: For the period from 1992 through 1999, 2702 incident <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> were reported in 138 148 person-years of observation, and more than 90% of them were either <z:hpo ids='HP_0100726'>Kaposi's sarcoma</z:hpo> or non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>The adjusted incidence rate for <z:hpo ids='HP_0100726'>Kaposi's sarcoma</z:hpo> declined from 15.2 in 1992 through 1996 to 4.9 in 1997 through 1999 (rate ratio = 0.32; 99% confidence interval [CI] = 0.26-0.40; based on 1489 and 190 cases, respectively; P&lt;.0001) </plain></SENT>
<SENT sid="9" pm="."><plain>The incidence rates for non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> also declined, from 6.2 to 3.6 (rate ratio = 0.58; 99% CI = 0.45-0.74; based on 623 and 134 cases, respectively; P&lt;.0001) </plain></SENT>
<SENT sid="10" pm="."><plain>Among the <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, the rate ratios were 0.42 (99% CI = 0.24-0.75) for cerebral <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 0.57 (99% CI = 0.39-0.85) for <z:e sem="disease" ids="C1521815" disease_type="Neoplastic Process" abbrv="">immunoblastic</z:e> <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and 1.18 (99% CI = 0.48-2.88) for Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (chi(2)(2) for <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> = 6.2; P: =.05) </plain></SENT>
<SENT sid="11" pm="."><plain>There was no statistically significant change in the incidence rates for <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> (rate ratio = 0.77; 99% CI = 0.32-1.85; based on 38 and 12 cases, respectively; P =.4) or for <z:e sem="disease" ids="C0302592" disease_type="Neoplastic Process" abbrv="">cervical cancer</z:e> (rate ratio = 1.87; 99% CI = 0.77-4.56; based on 19 and 17 cases, respectively; P =.07) </plain></SENT>
<SENT sid="12" pm="."><plain>The adjusted incidence rate for <z:hpo ids='HP_0000001'>all</z:hpo> other <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> combined was 1.7 in each time period (rate ratio = 0.96; 99% CI = 0.62-1.47; based on 126 and 54 cases, respectively) </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSIONS: Since the widespread use of HAART, there have been substantial reductions in the incidence <z:hpo ids='HP_0100726'>Kaposi's sarcoma</z:hpo> and non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in HIV-infected people but, so far, no substantial change in the incidence of other <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
</text></document>